Compare HURN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HURN | CELC |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.1B |
| IPO Year | 2004 | 2017 |
| Metric | HURN | CELC |
|---|---|---|
| Price | $179.87 | $102.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $199.00 | $100.13 |
| AVG Volume (30 Days) | 130.3K | ★ 870.9K |
| Earning Date | 10-28-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.32 | N/A |
| EPS | ★ 5.98 | N/A |
| Revenue | ★ $1,618,977,000.00 | N/A |
| Revenue This Year | $14.19 | N/A |
| Revenue Next Year | $9.49 | N/A |
| P/E Ratio | $30.20 | ★ N/A |
| Revenue Growth | ★ 12.67 | N/A |
| 52 Week Low | $120.25 | $7.58 |
| 52 Week High | $182.71 | $112.64 |
| Indicator | HURN | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 68.39 | 59.89 |
| Support Level | $178.00 | $97.27 |
| Resistance Level | $181.14 | $103.50 |
| Average True Range (ATR) | 4.82 | 4.47 |
| MACD | -0.02 | -1.13 |
| Stochastic Oscillator | 90.91 | 31.23 |
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.